BioLineRx, Hemispherian disclose promising data for glioblastoma candidate
BioLineRx (NASDAQ:BLRX) and Hemispherian AS announced encouraging preclinical data for their oncology candidate GLIX1, showcasing the experimental drug’s potential to combat glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer.










